Seminar – Ramaroson ANDRIANTSITOHAINA

Extracellular Vesicles‑Guided Delivery and NLRP3 Blockade: A Hypothalamic Therapeutic Roadmap for Atherosclerosis and Atrial Fibrillation

With more than 25 years of pioneering leadership in extracellular vesicle (EV) biology, Ramaroson Andriantsitohaina is internationally recognized for advancing EVs into powerful tools for understanding and treating cardiometabolic diseases. His work has helped establish EVs as biomarkers, intercellular communication vectors, and next‑generation biotherapeutics.

He integrates world‑class EV profiling in both animal models and human cohorts with the development of patented EV-based therapeutic platforms, including an innovative neuron‑targeted suppression system. His access to large, deeply phenotyped human plasma cohorts enables the rapid translation of mechanistic EV signatures into early diagnostic strategies and precision therapies, bridging fundamental discovery to clinical application.

A leading figure in cardiovascular and metabolic research, Ramaroson Andriantsitohaina has shaped the field through high‑impact translational contributions, including patents, clinical studies, and the coordination of major cohorts. He previously served as Director of UMR INSERM 1063 Angers Stress Oxydant et Pathologies Métaboliques and as Director of the Structure Fédérative de Recherche ICAT 4208 Interactions Cellulaires et Applications Thérapeutiques.